- Cheapest across the Hospital Industry, with 18x CFO to EBITDA - Cancer care is in the great tailwind across developed economies, which makes HCG a good play for the long run. As India evolves into a developed country, or India positions itself as a medical treatment outsourcer. - CEO is capable of envisioning a turnaround in the business
Technically::
- Highest strength across its industry peers - Fresh breakout of all-time high, may go 5-10x from this level in 5-7 years.
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.